Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
NCT ID: NCT00920725
Last Updated: 2012-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2005-01-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA
NCT00732524
Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis
NCT02006342
Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.
NCT00591227
Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis
NCT02930044
Comparison of a Low Dose to a Standard Dose of Insulin in Adult DKA in ICU to Reduce Metabolic Complications
NCT05443802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subcutaneous Insulin
Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours
Insulin (Aspart Insulin [Novolog], Regular Insulin)
Aspart Insulin 0.2units/sq q 2 hours
Regular Insulin 0.1units/kg/hr intravenous
Aspart Insulin 0.1 units/kg/hr intravenous
IV Regular Insulin
Intravenous Regular Insulin 0.1 units/kg/hour
Insulin (Aspart Insulin [Novolog], Regular Insulin)
Aspart Insulin 0.2units/sq q 2 hours
Regular Insulin 0.1units/kg/hr intravenous
Aspart Insulin 0.1 units/kg/hr intravenous
Intravenous Novolog Insulin
Intravenous Novolog Insulin 0.1 units/kg/hour
Insulin (Aspart Insulin [Novolog], Regular Insulin)
Aspart Insulin 0.2units/sq q 2 hours
Regular Insulin 0.1units/kg/hr intravenous
Aspart Insulin 0.1 units/kg/hr intravenous
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin (Aspart Insulin [Novolog], Regular Insulin)
Aspart Insulin 0.2units/sq q 2 hours
Regular Insulin 0.1units/kg/hr intravenous
Aspart Insulin 0.1 units/kg/hr intravenous
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 2 of the following 3:
1. serum HCO3 \< 18/anion gap \> 16
2. serum glucose \> 300 mg/dl
3. serum acetone positive
Exclusion Criteria
* less than age 18
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Rush University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Baldwin
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rema A Gupta, MD
Role: PRINCIPAL_INVESTIGATOR
Rush University Medical Center
David Baldwin, MD
Role: PRINCIPAL_INVESTIGATOR
Rush University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05012103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.